Vasoactive hormones and the diabetic kidney

Area of Science:

• Nephrology
• Endocrinology
• Vascular Biology

Background:

• Diabetic nephropathy is a leading cause of end-stage renal disease (ESRD), contributing to significant morbidity and mortality.
• While overall ESRD incidence has stabilized, disparities exist, with less improvement observed in certain populations like African Americans.
• Current treatments for diabetic nephropathy primarily involve the renin-angiotensin-aldosterone system (RAAS), including ACE inhibitors and ARBs.

Purpose of the Study:

• To review the current understanding of vasoactive hormones' contribution to diabetic nephropathy pathophysiology.
• To emphasize the role of the RAAS, including its recently identified components.
• To explore the involvement of other vasoactive systems like endothelin, urotensin II, and the kallikrein-kinin system (KKS).

Main Methods:

• Literature review of studies on vasoactive hormones and diabetic nephropathy.
• Analysis of data from the U.S. Renal Data System (USRDS) regarding ESRD trends.
• Focus on the renin-angiotensin-aldosterone system (RAAS) and other vasoactive pathways.

Main Results:

• ESRD incidence has stabilized, suggesting improvements in ESRD treatment and patient care.
• Significant disparities in ESRD decrease were noted, with less improvement in African Americans compared to young Caucasian men.
• Vasoactive hormones beyond RAAS, including endothelin, urotensin II, and KKS, are implicated in renal damage in diabetic nephropathy.

Conclusions:

• Despite overall stabilization, diabetic nephropathy remains a critical health issue with persistent racial disparities.
• Further research into specific patient groups and novel therapeutic strategies targeting vasoactive hormones is essential.
• Understanding the complex interplay of hormonal systems is key to eradicating diabetic nephropathy in all populations.